The UK health and fitness market has hit a new high, generating £5.7bn in annual revenue and reaching 11.5 million members across 5,607 clubs. A new industry report from ukactive, with analysis from Deloitte, highlights strong sector growth, rising gym usage, and major investment potential—even amid economic headwinds.

New research reveals UK-based fitness chain The Gym Group has generated $2.25 billion USD in social value since 2016—improving health, education outcomes, and reducing crime. It’s the first private operator to measure its impact using Sport England’s Social Value Calculator.

The NHS is urging clinicians to integrate physical activity into routine care, citing its role in preventing and managing chronic conditions—and the billions it could save the healthcare system.

Life Time has launched its LTH supplement line on Amazon, making more than 50 research-backed products accessible to a wider audience. The move comes as 71% of U.S. adults report confusion around supplement choices.

Garmin’s fēnix smartwatches are supporting spaceflight research on the Fram2 mission, collecting biometric data in orbit. Here’s what it means for the future of wearables in fitness and health monitoring.

Noom has partnered with LillyDirect® pharmacy provider Gifthealth to streamline access to Zepbound® vials for weight management, enhancing its GLP-1 Companion program for eligible users.

GymNation is turning heads with its latest concept — an in-gym hotel promising recovery without the commute. Dumbbell-shaped towels, protein-on-demand, and "Gymflix" are just the beginning. Is this the future of fitness, or something a little more tongue-in-cheek?

Novo Nordisk says unauthorized compounded versions of Wegovy are cutting into U.S. sales and warns it may pursue legal action to protect its intellectual property. The company has also expanded access to its official savings program.

Discover how F45 Training and Dr. B are addressing the rising demand for GLP-1 medications by combining fitness, nutrition, and telehealth solutions to support sustainable weight management.

Biden Administration proposes expanding Medicare and Medicaid to cover GLP-1 medications, addressing obesity and opening new opportunities for the fitness industry. Learn how this could reshape access to care and gym engagement.

Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.

Discover the unexpected U.S. state leading the surge in GLP-1 weight loss drug usage, driven by celebrity endorsements and healthcare innovations, with significant economic implications.

Explore the shift in GLP-1 drug use as a growing number of non-diabetics turn to these medications for weight loss. Understand the new trends and their impact on diabetes care.

New analysis reveals 85% of individuals stop using GLP-1 drugs for weight loss after two years. Learn about adherence trends and the role of fitness centers like Equinox and MIORA by Life Time in obesity management.

Discover how Ozempic and other GLP-1 agonists may reduce the risk of obesity-associated cancers in a recent study of obese patients. Learn more about the potential cancer-preventive effects of these diabetes medications.

Discover how GLP-1 agonist drugs are becoming increasingly popular among adults, with 43% now using them for weight loss and chronic conditions. Learn about the rising awareness and affordability challenges revealed in the latest poll.

Discover how Nestlé Health Science is addressing the growing GLP-1 medication market with their new nutrition platform and Vital Pursuit food line, designed to support weight management and wellness.

Discover Ro's new GLP-1 Supply Tracker, providing real-time insights into GLP-1 drug shortages. Learn how this tool helps manage medication availability as demand for weight loss drugs rises.

New research from the University of Aberdeen reveals how physical fitness influences the body's metabolism of saturated fat. Discover how exercise impacts fat utilization and improves overall metabolic health.

Discover strategies to mitigate the high costs of discontinuing GLP-1 medications. Learn how employers can plan for effective weight management and ensure long-term adherence.